# EDGAR Filing Document

**Accession Number:** 0001832332
**File Stem:** 0001193125-25-282983
**Filing Date:** 2025-11
**Character Count:** 23267
**Document Hash:** b70536f3218f1b70ca4389f909199746
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-282983.hdr.sgml**: 20251114

**ACCESSION NUMBER**: 0001193125-25-282983

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251113

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251114

**DATE AS OF CHANGE**: 20251114

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aveanna Healthcare Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001832332
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HOME HEALTH CARE SERVICES [8082]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 844717209
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0101

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40362
- **FILM NUMBER:** 251486450

**BUSINESS ADDRESS:**
- **STREET 1:** 400 INTERSTATE NORTH PARKWAY
- **STREET 2:** STE 1700
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30339
- **BUSINESS PHONE:** 770-441-1580

**MAIL ADDRESS:**
- **STREET 1:** 400 INTERSTATE NORTH PARKWAY
- **STREET 2:** STE 1700
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30339

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** November 13, 2025<br>

------

![img25621588_0.jpg](img25621588_0.jpg)

Aveanna Healthcare Holdings Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40362 | 81-4717209 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 400 Interstate North Parkway SE |  |  |
| Atlanta**,** Georgia |  | 30339 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 770 441-1580<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | AVAH | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 1.01 Entry Into a Material Definitive Agreement.**

On November 13, 2025, Aveanna Healthcare Holdings Inc. (the "Company") entered into a second amendment (the "Second Amendment") to that certain Amended and Restated Stockholders Agreement (as amended, the "A&R Stockholders Agreement") with certain affiliates of Bain Capital L.P. ("Bain"), certain affiliates of J.H. Whitney Capital Partners ("Whitney" and, together with Bain, the "Sponsor Affiliates") and certain other parties thereto.

Pursuant to the Second Amendment, certain executives of the Company (the "Executives") that are party to the A&R Stockholders Agreement may only sell, transfer, assign, pledge or otherwise directly or indirectly dispose of ("Transfer") shares of the Company's common stock (the "Common Stock") to the extent that such Transfer (a) is pre-approved by the Compensation Committee (the "Compensation Committee") of the Board of Directors (the "Board") and (b) would not result in such Executive being in non-compliance with the Company's Stock Ownership Guidelines. Transfers made in connection with "sell to cover" or similar transactions intended to satisfy the exercise price or tax withholding obligations of equity awards held by an Executive are exempt from the above-described restrictions on Transfers. The Second Amendment further provides that certain Other Stockholders (as defined in the A&R Stockholders Agreement) may Transfer shares of Common Stock without restriction or the consent of any other person.

The foregoing description of the Second Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Second Amendment, a copy of which is filed herewith as Exhibit 10.1 and incorporated by reference herein.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 13, 2025, Christopher Gordon informed the Board of his decision to resign from his position as a Class II director of the Board, effective immediately. The decision by Mr. Gordon to resign from the Board was not the result of any disagreement with the Company on any matter regarding the Company's operations, policies or practices.

Mr. Weil, age 35, joined Bain in 2015, where he currently serves as a Principal and member of the North America private equity team focused on investments in the Healthcare sub-sectors including healthcare delivery and life sciences. Prior to joining Bain Capital, he was a management consultant at McKinsey & Company, where he focused primarily on strategy and operations for clients across the healthcare industry.

Mr. Weil was appointed to the Board as a Class II director in accordance with the A&R Stockholders Agreement, pursuant to which the Company has committed to take necessary action to appoint a director designated by Bain to fill a vacancy created due to the departure of a director previously designated by Bain, subject to certain equity ownership levels.

Since the beginning of the Company's last fiscal year, there have been no transactions, and there are no currently proposed transactions, to which the Company was or is a participant and in which Mr. Weil had or is to have a direct or indirect material interest that would require disclosure pursuant to Item 404(a) of Regulation S-K.

As a non-employee director who is affiliated with Bain, Mr. Weil will not receive compensation in accordance with the Company's current non-employee director compensation policy.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit Number** | <br>**Description** |
| 10.1 | [<u>Second Amendment to the Amended and Restated Stockholders Agreement entered into on November 13, 2025</u>](avah-ex10_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | AVEANNA HEALTHCARE HOLDINGS INC. |
| Date: | November 14, 2025 | By:  | /s/ Jeff Shaner |
|  |  |  | **Jeff Shaner <br>Chief Executive Officer<br>(Principal Executive Officer)** |

---

------

## Exhibit 10.1

*Exhibit 10.1*

**AVEANNA HEALTHCARE HOLDINGS INC.**

**SECOND AMENDMENT TO**

**AMENDED AND RESTATED STOCKHOLDERS AGREEMENT**

THIS SECOND AMENDMENT TO THE AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this "Amendment"), effective as of November 13, 2025 (the "Effective Date"), is made by and among (i) Aveanna Healthcare Holdings Inc., a Delaware corporation (the "Company"), (ii) BCPE Eagle Investor, LP ("Bain Sponsor"), (iii) (a) J.H. Whitney VII, L.P., (b) PSA Healthcare Investment Holding LLC and (c) PSA Iliad Holdings LLC (clauses (a), (b) and (c) together, "Whitney Sponsors") (each, individually, a "Party" and together, the "Parties"). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement (as defined below).

RECITALS

WHEREAS, the Company and certain Stockholders entered into that certain Amended and Restated Stockholders Agreement, dated May 3, 2021 (as amended from time to time, the "Agreement");

WHEREAS, Section 11(a) of the Agreement provides that the provisions of the Agreement may be amended, modified or waived only with the prior written consent of each Sponsor holding at least 1% of the outstanding shares of voting Company Capital Stock on a fully-diluted basis (each, a "Consenting Sponsor"); and

WHEREAS, Bain Sponsor and Whitney Sponsors, being the only Consenting Sponsors as of the Effective Date, and the Company desire to amend the Agreement as set forth herein pursuant to Section 11(a) of the Agreement.

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises contained in this Amendment, and other good and valuable consideration, and intending to be legally bound thereby, the Parties hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.<u>Amendment</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Section 1 of the Agreement is hereby amended to delete the definition of "Coordination Committee".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Section 3(a)(i) of the Agreement is hereby deleted and replaced in its entirety with the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Public Transfers</u>. Any Stockholder may, subject to the terms of the Registration Rights Agreement, sell, transfer, assign, pledge or otherwise directly or indirectly dispose of, whether with or without consideration and whether voluntarily or involuntarily or by operation of law ("<u>Transfer</u>" or, if used as a noun, a "<u>Transfer</u>") any or all of such Stockholder's Stockholder Shares without the consent of any other Person in a Public Sale; <u>provided</u>, that (x) in the case of an Other Stockholder, such Other Stockholder may only Transfer to the extent such Transfer would not result in the Relative Ownership Percentage of such Other Stockholder immediately following such Transfer being less than the Relative Ownership Percentage of the Sponsors immediately following such Transfer and (y) if, due to this Agreement, the Registration Rights Agreement or any other agreement, any Stockholders are deemed to constitute a single group for purposes of Rule 144 during any volume limit measurement period thereunder, such Stockholders will not be permitted to Transfer pursuant to Rule 144 during such measurement period more than their pro rata portion (determined, as of the commencement of such measurement period, as the percentage equal to (1) such Stockholder's aggregate number of Stockholder Shares divided by (2) the applicable Stockholders' aggregate number of Stockholder Shares) of

------

the aggregate number of Stockholder Shares that may be Transferred by such Stockholders within the constraints of such volume limit during such measurement period; <u>provided</u>, <u>further</u>, that the Other Stockholders listed on <u>Annex A</u> hereto shall not be subject to the Transfer restrictions described in the foregoing clause; <u>provided</u>, <u>further</u>, that in the case of an Executive listed on <u>Annex B</u> hereto, such Executive may only Transfer Stockholder Shares to the extent that (x) such Transfer is pre-approved by the Compensation Committee of the Board and (y) the Transfer would not result in the Executive listed on <u>Annex B</u> being in non-compliance with the Company's Stock Ownership Guidelines, as in effect on the date of the Transfer. Notwithstanding the foregoing or anything to the contrary in this Agreement, an Executive listed on <u>Annex B</u> shall be permitted to complete any Transfers (x) in connection with "sell to cover" or similar open market transactions to satisfy any exercise price or tax withholding obligations as a result of the exercise, vesting and/or settlement of the Company equity awards (including options and restricted stock units) that are held by such Executive and issued under the Company's stock incentive plan or other equity award plan (such equity awards, the "<u>Equity Awards</u>") and (y) to the Company in connection with the vesting, settlement or exercise of restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including, in each case, by way of "net" or "cashless" exercise), including any Transfer to the Company for the payment of exercise price, tax withholdings or remittance payments due as a result of the vesting, settlement or exercise of such restricted stock units, options, warrants or other rights, or in connection with the conversion of convertible securities, in all such cases pursuant to Equity Awards granted under a stock incentive plan or other equity award plan, or pursuant to the terms of convertible securities. For the purposes of this <u>Section 3(a)(i)</u>, "<u>Relative Ownership Percentage</u>" shall mean (A) with respect to the Stockholder Shares held by an Other Stockholder, a fraction (expressed as a percentage) (i) the numerator of which is the number of Stockholder Shares owned by such Other Stockholder immediately following the effective time of a Transfer and (ii) the denominator of which is the aggregate number of Stockholder Shares owned by such Other Stockholder at the time of the consummation of the IPO and (B) with respect to the Stockholder Shares held by the Sponsors, a fraction (expressed as a percentage) (i) the numerator of which is the aggregate number of Stockholder Shares owned by all of the Sponsors immediately following the effective time of such Transfer and (ii) the denominator of which is the aggregate number of Stockholder Shares owned by all of the Sponsors at the time of the consummation of the IPO.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Section 3(a)(ii) of the Agreement is hereby deleted and replaced in its entirety with the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Cooperation</u>. In connection with a proposed Transfer of Stockholder Shares by a Sponsor, the Company will provide, and will cause its controlled Affiliates to provide, such cooperation as may be reasonably requested by such Sponsor in connection with the prospective purchaser's due diligence investigation of the Company and its controlled Affiliates, including providing such proposed purchaser with reasonable access to the material contracts, properties, books and records of the Company and its controlled Affiliates and reasonable access to management on reasonable notice, subject to any such prospective purchaser entering into a customary confidentiality agreement in favor of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Section 8 of the Agreement is hereby deleted and replaced in its entirety with the following:

Section 8. [Reserved].

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.<u>Ratification of Binding Provisions</u>. All other paragraphs, provisions, and clauses in the Agreement not modified by this Amendment shall remain in full force and effect as originally written.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.<u>Electronic Delivery; Counterparts</u>. This Amendment, to the extent signed and delivered by electronic transmission showing the signature of a Party, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person by such Party. At the request of any Party hereto, each other Party hereto shall re-execute original forms thereof and deliver them to all other Parties. No Party hereto shall raise the use of electronic transmission to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through electronic means as a defense to the formation or enforceability of a contract and each such Party forever waives any such defense. This Amendment may be executed simultaneously in two or more counterparts, any one of which need not contain the signatures of more than one Party, but all such counterparts taken together shall constitute one and the same agreement.

\* \* \* \* \*

------

IN WITNESS WHEREOF, the Parties have executed this Amendment effective as of the Effective Date.

**AVEANNA HEALTHCARE HOLDINGS INC.**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Jeffrey Shaner |
| &nbsp;&nbsp;&nbsp;Name: | &nbsp;&nbsp;Jeffrey Shaner |
| &nbsp;&nbsp;&nbsp;Title: | &nbsp;&nbsp;Chief Executive Officer |

---

[Signature Page to Amendment to Amended and Restated Stockholders Agreement]

------

**BCPE EAGLE INVESTOR, LP**

By: BCPE Eagle GP, LLC

Its: General Partner

By: Bain Capital Fund XI, L.P.

Its: Member

By: Bain Capital Partners XI, L.P.

Its: General Partner

By: Bain Capital Investors, LLC

Its: General Partner

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Devin O'Reilly |
| &nbsp;&nbsp;&nbsp;Name: | &nbsp;&nbsp;&nbsp;Devin O'Reilly  |
| &nbsp;&nbsp;&nbsp;Title: | &nbsp;&nbsp;&nbsp;Authorized Signatory |

---

[Signature Page to Amendment to Amended and Restated Stockholders Agreement]

------

**J.H. WHITNEY VII, L.P.**

By: J.H. WHITNEY EQUITY PARTNERS VII, LLC

Its: General Partner

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Robert Williams |
| &nbsp;&nbsp;&nbsp;Name: | &nbsp;&nbsp;&nbsp;Robert Williams |
| &nbsp;&nbsp;&nbsp;Title: | &nbsp;&nbsp;&nbsp;Authorized Signatory |

---

**PSA HEALTHCARE INVESTMENT HOLDING LLC**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Robert Williams |
| &nbsp;&nbsp;&nbsp;Name: | &nbsp;&nbsp;&nbsp;Robert Williams |
| &nbsp;&nbsp;&nbsp;Title: | &nbsp;&nbsp;&nbsp;Authorized Signatory |

---

**PSA ILIAD HOLDINGS LLC**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Robert Williams |
| &nbsp;&nbsp;&nbsp;Name: | &nbsp;&nbsp;&nbsp;Robert Williams |
| &nbsp;&nbsp;&nbsp;Title: | &nbsp;&nbsp;&nbsp;Authorized Signatory |

---

[Signature Page to Amendment to Amended and Restated Stockholders Agreement]

------

**Annex A** 

**Other Stockholders Excluded from All Transfer Restrictions**

Shane Brinkerhoff

Michael Young

Matthew Haglund

Patrick Cunningham

Rachel Witt

Chandra Burns

James Elkington

Neal McDowell

Victor Lira

Mike Muncy

Jim Melancon

Becky Hobson

Rocky Gonzalez

Patrick Gauthier

Dave Afshar

Shannon Drake

Richard Zoretic

Sheldon Retchin

Victor Ganzi

Erica Schwartz

Steve Rodgers

Brent Layton

Melissa Jean Akail

Melissa Wildermuth Akali

Austin J. Albury

Jaun M. Andrus

Anthony P. Angelo

Paula Marie Arnold

Jonathan Beckler

Veronica L. Benson

Joseph D. Bettini

Crystal Blackshear

Jeffrey Blair

Nataly Blair

Leanna Bryant

Eduardo Bueno

Aaron Burris

Diana Bustos

Sidney Ha Cananea

Erin Carrell

Monica Castillo

Chassie L. Chairs

Danielle Chattin

Amanda Cifuentes

Leah Clark

Andrew P. Clinton

Jennifer Jean Combs

------

Lindsey Cook

Claire V. Cooper

Janet Mary Daly

Angele Italia DAmico

Steven Davidson

Rob Dennis

Marianne Lynn Dernbach

Roxanna Smith Donahue

Jennifer Ellis

Vicki Emch

Ingrid Justine Emmons

Selena Escalante

Cindy Leigh Everett

Janet Fehler

Michael R. Fiorelli

Jelyne Floro

Barbara Folts

Danialle Foster

Kara A. Fremont

Linda J. Fussell

Juan Manuel M. Garcia

Dorothy M. Gartman

Terin Glaser

Tammy Gronski

Jaimie A. Hall

Kim Hancock

Michael Harrington

Guy Montgomery Harris

Najet Hawkins

Shannon Heath

Teri Lynn Henning

George Hernandez

Eduardo A. Hinojosa

Jennifer W. Hocutt

Jacqueline Holland

Oni Holley-Brown

Dustin Frederick Holston

Alan Daniel Horowitz

Matthew Housden

Harriett Howard

Robert L. Howren

Joshua K. Hubbard

Alexandria Idstein

Leslie Terranella Ivory

Derrian James

Michael Javitt

Cody Jennings

Trevor Karagias

Catherine Kilkenny

Lisa J. Klimek

Marcus Koenig

------

Elizabeth Kowalczyk

Carsa Kruppenbach

LaThanya Lancaster

Regina Loraine Lane

Robin Lee

Christina Lizaola-Barela

Lisa Gentilella Loesser

Sasha Miranda Loffio

Adam L. Marconi

Eileen P. Martin

Kevin Mcbride

Toni-Ann McSharry

Annette Felicia Michael

Daniella Marie Millan-Portillo

David Kenneth Milton

Richard Montgomery

Alma Morales

Wesley Moss

Chomba Mwenya

Koushan Noorbehesht

Klacie Joanne Norris

Victoria Oliveira-Stewart

Erik Ollestad

Laurie Otis

Tracy L. Parker

David Pearce

Mary Peck

Gino Pici

Renee Pina

Adrienne Pyle

Julian Ramos

Reynaldo Ramos

Kelly S Reppart

Mario Reyna

Sarah E. Roberts

Shelley Stockman Roberts

Kristina Rodriguez

Mary Rummelhart

Stephanie Russell

Stephanie Schlenger

Paul Seugling

Colleen K. Shade

Joseph Sharp

Danal Slay

Blake Smith

Kyle Joseph Smith

Kate M. Speer

Meredith Spencer

Peyton K. Stephens

Nathan Stitley

Martin Stoleroff

------

Timothy Swann

Eric Sweeney

Susan M. Tamburin

Lisa K. Teel

Bryce Trammell

Linda Trelstad

Loredana Vacarasu

Baobay Xiong Vang

Victoria Vasquez

Brandon Wakil

Karlene Watts

Melissa M. Wilbanks

Ashley Price Wilcox

Amanda Wright

Kelly Ann York

------

**Annex B**

**Executives**

Rodney Windley

Jeffrey Shaner

Matthew Buckhalter

Deborah Stewart

Jerry Perchik

Ed Reisz

Kristy Rohwedder

------